A multitude of new agents for the treatment of hematologic malignancies has been
introduced over the past decade. Hematologists, infectious disease specialists, stem cell …

Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …

In patients with hematologic malignancies due to immune system disorders, especially
persistent febrile neutropenia, invasive fungal infections (IFI) occur with high mortality …

Higher risks of infection are associated with some targeted drugs used to treat solid organ
and hematological malignancies, and an individual patient's risk of infection is strongly …

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is increasingly used in the treatment of
chronic lymphocytic leukemia (CLL). Moreover, very promising results have been reported in …

The use of cytotoxic chemotherapy in the treatment of malignant and inflammatory disorders
is beset by considerable adverse effects related to nonspecific cytotoxicity. Accordingly, a …

Abstract Purpose of Review This review discusses fungal infections associated with licenced
small-molecule protein kinase inhibitors. For each major drug class, the mechanism of …

Simple Summary Targeted therapies have revolutionized the management of hematological
malignancies and solid organ cancers. These new treatments present numerous infectious …

Purpose Invasive fungal diseases and especially Cryptococcus neoformans infections are
increasingly reported in patients with hematological malignancies receiving ibrutinib, a …

Cryptococcus is an opportunistic fungal pathogen that can cause disseminated infection with
predominant central nervous system involvement in patients with compromised immunity …